THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

genedrive plc

("genedrive" or the "Company")

Agreement of Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in the Company, the Company is pleased to confirm today that definitive agreements have now been signed for the Loan.

Further terms of the Loan and Related Party Transaction

The Company and David Nugent have entered into a Loan Agreement for up to £1.0 million in value (the "Loan"). The Loan is available to be drawn in two equal tranches of £500,000. The first tranche shall be requested imminently and shall not attract any commitment fee, interest or charges. The first tranche is expected to extend the Company's cash runway into February 2026. The second tranche will be available to be drawn down at the request and discretion of the Company on or after 20 February 2026 (or such other date as may be agreed between the Company and David Nugent). Draw down of the second tranche would incur a fixed fee of £50,000 which shall be added to the amount of principal and would need to be repaid upon repayment or conversion of the second tranche. The loan shall be secured by the grant of a debenture over all the Company's assets and is for a maximum period of twelve months. David Nugent currently intends that all amounts of the Loan drawn down shall be converted into equity as part of a future equity raise.

David Nugent is a related party of the Company pursuant to the AIM Rules and him being a party to the Loan constitutes a related party transaction for the purposes of AIM Rule 13. The Directors consider, having consulted with the Company's nominated adviser, Peel Hunt LLP, that the Company entering to the Loan with David Nugent is fair and reasonable insofar as Shareholders are concerned.

Dr Gino Miele, CEO of genedrive plc, said: "On behalf of the Company I extend my gratitude to David for providing this Loan on the terms now agreed.  The Loan provides a valuable extension to our cash runway whist we continue to execute against our commercial and strategic goals and work towards longer term financing options."

Mr David Nugent, said: "I am delighted to provide this Loan to the Company as I am determined to ensure that the Company has the financial and other resources it needs to deliver for both patients and shareholders.  As a significant shareholder in the Company I am also encouraged by the recent progress within genedrive which has coincided with a significant recovery in the Company's share price and I intend to provide further financial support to the Company going forwards."

For further details please contact:

About genedrive plc ( http://www.genedrive.com )

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.